How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegintron-riba.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Pegintron + Riba — Competitive Intelligence Brief

Pegintron + Riba (Pegintron + Riba) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy (interferon + nucleoside analog). Area: Virology/Hepatology.

marketed Antiviral combination therapy (interferon + nucleoside analog) Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Pegintron + Riba (Pegintron + Riba) — Chang Gung Memorial Hospital. Pegintron (pegylated interferon alfa-2b) and ribavirin work together to inhibit hepatitis C virus replication by enhancing innate immune responses and directly blocking viral RNA synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pegintron + Riba TARGET	Pegintron + Riba	Chang Gung Memorial Hospital	marketed	Antiviral combination therapy (interferon + nucleoside analog)	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Xenical, Pegasys, Copegus	Xenical, Pegasys, Copegus	Brooke Army Medical Center	marketed	Antiviral combination therapy (interferon + nucleoside analog); Lipase inhibitor	Hepatitis C virus NS5B polymerase; pancreatic lipase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy (interferon + nucleoside analog) class)

Chang Gung Memorial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegintron + Riba — Competitive Intelligence Brief. https://druglandscape.com/ci/pegintron-riba. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab